Notably, analysis of patient tumor data indicates that colorectal cancers and other solid tumors, such as pancreatic and stomach cancers, have higher levels of MUC13. Thus, patients with tumors having high MUC13 levels could be the ones to benefit most from treatment with the BNC (Fig. 7g). This evidence concerns the gene MUC13 and gastric cancer.